BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 27677741)

  • 1. Pharmacogenomics and chemical library screens reveal a novel SCF
    Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
    Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
    Chen Q; Xie W; Kuhn DJ; Voorhees PM; Lopez-Girona A; Mendy D; Corral LG; Krenitsky VP; Xu W; Moutouh-de Parseval L; Webb DR; Mercurio F; Nakayama KI; Nakayama K; Orlowski RZ
    Blood; 2008 May; 111(9):4690-9. PubMed ID: 18305219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
    Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
    Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate.
    Bornstein G; Ganoth D; Hershko A
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11515-20. PubMed ID: 16861300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific small molecule inhibitors of Skp2-mediated p27 degradation.
    Wu L; Grigoryan AV; Li Y; Hao B; Pagano M; Cardozo TJ
    Chem Biol; 2012 Dec; 19(12):1515-24. PubMed ID: 23261596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
    Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor.
    Cheng X; Liu YQ; Wang GZ; Yang LN; Lu YZ; Li XC; Zhou B; Qu LW; Wang XL; Cheng YX; Liu J; Tao SC; Zhou GB
    Oncotarget; 2017 Jan; 8(2):2681-2693. PubMed ID: 27835873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
    He DH; Chen YF; Zhou YL; Zhang SB; Hong M; Yu X; Wei SF; Fan XZ; Li SY; Wang Q; Lu Y; Liu YQ
    Cancer Sci; 2021 Aug; 112(8):3218-3232. PubMed ID: 34080260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
    Jia C; Kong D; Guo Y; Li L; Quan L
    Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
    Zhan F; Colla S; Wu X; Chen B; Stewart JP; Kuehl WM; Barlogie B; Shaughnessy JD
    Blood; 2007 Jun; 109(11):4995-5001. PubMed ID: 17303695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
    Bochis OV; Irimie A; Pichler M; Berindan-Neagoe I
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):225-34. PubMed ID: 26114183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
    Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
    Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
    Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
    J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skp2 is associated with paclitaxel resistance in prostate cancer cells.
    Yang Y; Lu Y; Wang L; Mizokami A; Keller ET; Zhang J; Fu J
    Oncol Rep; 2016 Jul; 36(1):559-66. PubMed ID: 27175797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.